11. Lahra MM, Ward A, Trembizki E, et al. Treatment guidelines after an outbreak of azithromycin- resistant Neisseria gonorrhoeae in South Australia. Lancet Infect Dis 2017; 17(2): 133-134. doi: 10.1016/S1473-3099(17) 30007-5.
12. Wind CM, Schim van der Loeff MF, van Dam AP, et al. Trends in antimicrobial susceptibility for azithromycin and ceftriaxone in Neisseria gonorrhoeae isolates in Amsterdam, the Netherlands, between 2012 and 2015. Euro Surveill 2017; 22(1). doi: 10.2807/1560-7917. ES.2017.22.1.30431.
13. Fifer H, Cole M, Hughes G, et al. Sustained transmission of high-level azithromycin-resistant Neisseria gonorrhoeae in England: an observational study. Lancet Infect Dis 2018; 18(5): 573- 581. doi: 10.1016/S1473-3099(18)30122-1.
14. Katz AR, Komeya AY, Kirkcaldy RD, et al. Cluster of Neisseria gonorrhoeae Isolates With High- level Azithromycin Resistance and Decreased Ceftriaxone Susceptibility, Hawaii, 2016. Clin Infect Dis 2017; 65(6): 918-923. doi: 10.1093/cid/cix485.
15. Ross JD, Harding J, Duley L, et al. LB1.5 The efficacy and safety of gentamicin for the treatment of genital, pharyngeal and rectal gonorrhoea: a randomised con- trolled trial. Sexually Transmitted Infections 2017; 93(Suppl 2): A42-A43. doi: 10.1136/sextrans-2017-053264.106.
16. Handsfield HH, Dalu ZA, Martin DH, et al. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Azithromycin Gonorrhea Study Group. Sex Transm Dis 1994; 21(2): 107-111.
17. Zheng S, Matzneller P, Zeitlinger M, et al. Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects. Antimicrob Agents Chemother 2014; 58(11): 6675-6684. doi: 10.1128/AAC.02904-14.
18. Matzneller P, Krasniqi S, Kinzig M, et al. Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. Antimicrob Agents Chemother 2013; 57(4): 1736- 1742. doi: 10.1128/AAC.02011-12.
19. Crokaert F, Hubloux A and Cauchie P. A Phase I Determination of Azithromycin in Plasma during a 6-Week Period in Normal Volunteers after a Standard Dose of 500mg Once Daily for 3 Days. Clin Drug Investig 1998; 16(2): 161-166.

*   Azithromycin 1g은 ceftriaxone에 대한 감수성이 감소된 임균 감염의 성공적인 치료를 보장하기 위해 2016년 권장 요법에 추가되었다. 하지만 in vitro에서 cephalosporin과 azithromycin 간의 시너지 효과를 암시하는 증거는 결정적이지 않다.
*   최근 우리나라를 비롯하여 전 세계적으로 azithromycin 내성 유병률이 증가했다. 또한 높은 수준의 azithromycin 내성 N. gonorrhoeae가 지속적으로 전파되었으며 세계 여러 나 라에서 보고되고 있다.
*   국제적으로 보고된 ceftriaxone 내성 분리주 중 일부가 azithromycin에 감수성이 있지만, azithromycin 1g 용량은 감염을 제거하는 데 불충분할 수 있다. 무작위대조시험(RCT)에 서 gentamicin 240mg IM과 azithromycin 1g 병용은 참여자의 91%에서만 감염을 제거

<PAGE>106